A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency

PHASE3CompletedINTERVENTIONAL
Enrollment

146

Participants

Timeline

Start Date

November 13, 2017

Primary Completion Date

March 19, 2019

Study Completion Date

March 19, 2019

Conditions
Growth Hormone Deficiency, PediatricEndocrine System DiseasesHormone DeficiencyPituitary Diseases
Interventions
DRUG

TransCon hGH

Once weekly subcutaneous injection at a starting dose of 0.24 mg/kg/week

Trial Locations (24)

1023

The Liggins Institute, The University of Auckland, Grafton

3168

Monash Children's Hospital, Clayton

10029

Icahn School of Medicine at Mount Sinai, New York

11501

NYU Winthrop Hospital, Mineola

22903

University of Virginia Children's Hospital, Charlottesville

23507

Children's Hospital of The King's Daughters, Norfolk

32207

Nemours Children's Health System, Jacksonville

32308

Tallahassee Memorial Hospital, Tallahassee

32806

Orlando Health Inc., Orlando

35233

University of Alabama, Birmingham

39216

University of Mississippi Medical Center, Jackson

44195

Cleveland Clinic Foundation, Cleveland

52242

University of Iowa, Iowa City

55102

Children's Minnesota, Saint Paul

73104

University of Oklahoma Health Sciences Center, Oklahoma City

75235

Children's Medical Center, Dallas

76104

Cook Children's Medical Center, Fort Worth

80112

Rocky Mountain Pediatric Endocrinology, Centennial

90048

Neufeld Medical Group Inc., Los Angeles

95821

Center of Excellence in Diabetes and Endocrinology, Sacramento

97227

Children's Diabetes and Endocrine Center, Portland

97239

Oregon Health & Science University, Portland

03756

Dartmouth Hitchcock Medical Center, Lebanon

T6G 2B7

Stollery Children's Hospital, Edmonton

All Listed Sponsors
lead

Ascendis Pharma Endocrinology Division A/S

INDUSTRY

NCT03305016 - A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency | Biotech Hunter | Biotech Hunter